Retinoblastoma is the most common intraocular malignancy of infants and children. With early diagnosis and treatment, survival is greater than 90%; however, patients with a germline retinoblastoma mutation have a substantial risk of having a second high-grade malignancy.
Methods
The recent developments in the diagnosis and treatment of retinoblastoma are reviewed.
Results
Identification of the retinoblastoma germline mutation is now possible with the discovery of the retinoblastoma gene. Patients with the germline mutation have a 51% cumulative risk over 50 years of developing a second malignancy. Several pilot studies using primary chemotherapy for retinoblastoma have shown promising results.
Conclusions
Risk assessment and genetic counseling have become more precise with the development of laboratory methods to identify the retinoblastoma gene. The development of primary chemotherapy regimens to reduce the size of retinoblastoma tumors may decrease the need for radiation therapy and thereby reduce the risk of radiation-related malignancies in patients with the germline mutation.
Get full access to this article
View all access options for this article.
References
1.
AlbertD.M.Historic review of retinoblastoma. Ophthalmology.1987; 94: 654–662.
2.
BishopJ.O., MadsonE.C.Retinoblastoma: review of the current status. Surv Ophthalmol.1975; 19: 342–366.
3.
ShieldsJ.A., AugsburgerJ.J.Current approaches to the diagnosis and management of retinoblastoma. Surv Ophthalmol.1981; 25: 347–372.
4.
MurphreeL.A.Molecular genetics of retinoblastoma. Ophthalmol Clin N Am.1995; 8: 155–166.
5.
KnudsonA.G.Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A.1971; 68: 820–823.
6.
TamboliA., PodgorM.J., HormJ.W.The incidence of retinoblastoma in the United States: 1974 through 1985. Arch Ophthalmol.1990; 108: 128–132.
7.
DevesaS.S.The incidence of retinoblastoma. Am J Ophthalmol.1975; 80: 263–265.
8.
PendergrassT.W., DavisS.Incidence of retinoblastoma in the United States. Arch Ophthalmol.1980; 98: 1204–1210.
9.
BayerJ., TalbertJ.L., DonnellyW.H.Childhood cancer care in Florida. J Fla Med Assoc.1984; 71: 777–781.
10.
RoushS.W., KrischerJ.P., PollockN.C.The incidence of pediatric cancer in Florida, 1981 to 1986. Cancer.1992; 69: 2212–2219.
11.
BooksteinR., LeeE.Y., ToH.Human retinoblastoma susceptibility gene: genomic organization and analysis of heterozygous intragenic deletion mutants. Proc Natl Acad Sci U S A.1988; 85: 2210–2214.
12.
HongF.D., HuangH.J., ToH.Structure of the human retinoblastoma gene. Proc Natl Acad Sci U S A.1989; 86: 5502–5506.
13.
HamelP.A., GillR.M., PhillipsR.A.Regions controlling hyperphosphorylation and conformation of the retinoblastoma gene product are independent of domains required for transcriptional repression. Oncogene.1992; 7: 693–701.
14.
ZamanianM., La ThangueN.B.Adenovirus E1a prevents the retinoblastoma gene product from repressing the activity of a cellular transcription factor. EMBO J.1992; 11: 2603–2610.
15.
HuQ.J., LeesJ.A., BuchkovichK.J.The retinoblastoma protein physically associates with the human cdc2 kinase. Mol Cell Biol.1992; 12: 971–980.
MargoC.E., ZimmermanL.E.Retinoblastoma: the accuracy of clinical diagnosis in children treated by enucleation. J Pediatr Ophthalmol Strabismus.1983; 20: 227–229.
18.
KopelmanJ.E., McLeanI.W.Multivariant analysis of clinical and histological risk factors for metastatic retinoblastoma. Invest Ophthalmol Vis Sci.1983; 24(suppl): 50.
FlexnerS.A peculiar glioma (neuroepithelioma) of the retina. Bull Johns Hopkins Hosp.1891; 2: 115–119.
21.
WintersteinerH.Die Neuroepithelioma Retinae: Eine Anatomiche und Klnische Studie.Leipzig, Germany: Dentisae; 1897.
22.
VerhoeffF.H.Retinoblastoma. Trans Am Ophthalmol Soc.1929; 24: 38–41.
23.
Ts'oM.O., ZimmermanL.E., FineB.S.The nature of retinoblastoma, I: photoreceptor differentiation: a clinical and histopathologic study. Am J Ophthalmol.1970; 69: 339–349.
24.
Ts'oM.O., FineB.S., ZimmermanL.E.The nature of retinoblastoma. II: photoreceptor differentiation: an electron microscopic study. Am J Ophthalmol.1970; 69: 350–359.
25.
KyritsisA.P., TsokosM., TricheT.J.Retinoblastoma: origin from a primitive neuroectodermal cell?Nature.1984; 307: 471–473.
26.
NorkT.M., SchwartzT.L., DoshiH.M.Retinoblastoma: cell of origin. Arch Ophthalmol.1995; 113: 791–802.
27.
GallieB.L., EllsworthR.M., AbramsonD.H.Retinoma: spontaneous regression of retinoblastoma or benign manifestation of the mutation?Br J Cancer.1982; 45: 513–521.
28.
MargoC., HidayatA., KopelmanJ.Retinocytoma: a benign variant of retinoblastoma. Arch Ophthalmol.1983; 101: 1519–1531.
29.
WongF.L., BoiceJ.D.Jr, AbramsonD.H.Cancer incidence after retinoblastoma: radiation dose and sarcoma risk. JAMA.1997; 278: 1262–1267.
30.
RoartyJ.D., McCleanI.W., ZimmermanL.E.Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology.1988; 95: 1583–1587.
31.
DraperG.J., SandersB.M., KingstonJ.E.Second primary neoplasms in patients with retinoblastoma. Br J Cancer.1986; 53: 661–671.
32.
TraboulsiE.I., ZimmermanL.E., ManzH.J.Cutaneous malignant melanoma in survivors of heritable retinoblastoma. Arch Ophthalmol.1988; 106: 1059–1061.
33.
BaderJ.L., MeadowsA.T., ZimmermanL.E.Bilateral retinoblastoma with ectopic intracranial retinoblastoma: trilateral retinoblastoma. Cancer Genet Cytogenet.1982; 5: 203–213.
34.
DonosoL.A., RorkeL.B., ShieldsJ.A.S-antigen immunoreactivity in trilateral retinoblastoma. Am J Ophthalmol.1987; 103: 57–62.
35.
DraperG.J., SandersB.M., BrownbillP.A.Patterns of risk of hereditary retinoblastoma and applications to genetic counselling. Br J Cancer.1992; 66: 211–219.
36.
GallieB.L.Predictive testing for retinoblastoma comes of age. Am J Hum Genet.1997; 61: 279–281.
37.
DryjaT.Assessment of risk in hereditary retinoblastoma. In: AlbertD.M., JakobiecF.A., eds. Principles and Practice of Ophthalmology: Basic Sciences.Philadelphia, Pa: WB Saunders Co; 1994.
38.
ShieldsJ.A., ShieldsC.L., SivalingamV.Decreasing frequency of enucleation in patients with retinoblastoma. Am J Ophthalmol.1989; 108: 185–188.
39.
AbramsonD.H., NiksarliK., EllsworthR.M.Changing trends in the management of retinoblastoma: 1951–1965 vs 1966–1980. J Pediatr Ophthalmol Strabismus.1994; 31: 32–37.
40.
SandersB.M., DraperG.J., KingstonJ.E.Retinoblastoma in Great Britain 1969–1980: incidence, treatment, and survival. Br J Ophthalmol.1988; 72: 576–583.
41.
GreenwaldM.J., StraussL.C.Treatment of intraocular retinoblastoma with carboplatin and etoposide chemotherapy. Ophthalmology.1996; 103: 1989–1997.
42.
GallieB.L., BudningA., DeBoerG.Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol.1996; 114: 1321–1328.
43.
ShieldsC.L., De PotterP., HimelsteinB.P.Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol.1996; 114: 1330–1338.
44.
KingstonJ.E., HungerfordJ.L., MadreperlaS.A.Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol.1996; 114: 1339–1343.
45.
MurphreeA.L., VillablancaJ.G., DeeganWFIII. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol.1996; 114: 1348–1356.
